These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 28603052)
1. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052 [TBL] [Abstract][Full Text] [Related]
2. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G; Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991 [TBL] [Abstract][Full Text] [Related]
4. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis. Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Tushuizen ME; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Baven Pronk MAMC; Beuers U; van der Meer AJ; Gerven NMFV; Sijtsma MGM; van Eijck BC; van IJzendoorn MC; van Herwaarden M; van den Brand FF; Korkmaz KS; van den Berg AP; Guichelaar MMJ; Levens AD; van Hoek B; Drenth JPH; J Hepatol; 2024 Apr; 80(4):576-585. PubMed ID: 38101756 [TBL] [Abstract][Full Text] [Related]
5. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial. Stoelinga AEC; Tushuizen ME; van den Hout WB; Girondo MDMR; de Vries ES; Levens AD; Moes DAR; Gevers TJG; van der Meer S; Brouwer HT; de Jonge HJM; de Boer YS; Beuers UHW; van der Meer AJ; van den Berg AP; Guichelaar MMJ; Drenth JPH; van Hoek B; Trials; 2024 Jan; 25(1):61. PubMed ID: 38233878 [TBL] [Abstract][Full Text] [Related]
6. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Chatur N; Ramji A; Bain VG; Ma MM; Marotta PJ; Ghent CN; Lilly LB; Heathcote EJ; Deschenes M; Lee SS; Steinbrecher UP; Yoshida EM Liver Int; 2005 Aug; 25(4):723-7. PubMed ID: 15998421 [TBL] [Abstract][Full Text] [Related]
7. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238 [TBL] [Abstract][Full Text] [Related]
8. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? Abdollahi M; Ekrami NK; Ghojazadeh M; Boezen HM; Somi M; Alizadeh BZ World J Gastroenterol; 2020 Oct; 26(38):5896-5910. PubMed ID: 33132643 [TBL] [Abstract][Full Text] [Related]
9. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559 [TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Santiago P; Schwartz I; Tamariz L; Levy C Aliment Pharmacol Ther; 2019 Apr; 49(7):830-839. PubMed ID: 30761563 [TBL] [Abstract][Full Text] [Related]
11. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children. Basu B; Babu BG; Mahapatra TK Clin Exp Nephrol; 2017 Feb; 21(1):143-151. PubMed ID: 27108294 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Wang J; Mao J; Chen J; Fu H; Shen H; Zhu X; Liu A; Shu Q; Du L Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959 [TBL] [Abstract][Full Text] [Related]
14. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074 [TBL] [Abstract][Full Text] [Related]